NCT05498220 2026-04-16
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
Clinical Trials
322 trialsNCT03520686 2026-04-15
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
ImmunityBio, Inc.
Phase 3 Terminated
NCT02819752 2026-04-09
PEACH
Royal Marsden NHS Foundation Trust
Phase 1 Terminated
NCT05839119 2026-04-02
TASUC-Neo
Brown University
Phase 1 Terminated
NCT03288545 2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2 Terminated
NCT02997332 2026-03-23
MEDINDUCTION
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Terminated
NCT00421096 2026-03-13
GEMCOL
Centre Oscar Lambret
Phase 2 Terminated
NCT04832854 2026-03-11
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT03631199 2026-02-25
CANOPY-1
Novartis
Phase 3 Terminated
NCT03366766 2026-02-20
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT04203160 2025-12-31
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
NCT04765709 2025-12-16
BRIDGE
Mario Negri Institute for Pharmacological Research
Phase 2 Terminated
NCT04854499 2025-11-19
ELEVATE HNSCC
Gilead Sciences
Phase 2 Terminated
NCT04524689 2025-10-29
CARMEN-LC05
Sanofi
Phase 2 Terminated
NCT04402073 2025-10-23
PersoMed-I
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT01495676 2025-10-10
GETUGV04
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Terminated
NCT04459715 2025-10-08
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
EMD Serono
Phase 3 Terminated
NCT04458909 2025-10-03
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
National Cancer Institute (NCI)
Phase 3 Terminated
NCT06056310 2025-09-29
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
EMD Serono
Phase 1 Terminated
NCT04887831 2025-09-08
PRESERVE3
G1 Therapeutics, Inc.
Phase 2 Terminated
NCT03656536 2025-08-24
FIGHT-302
Incyte Corporation
Phase 3 Terminated
NCT02784795 2025-08-21
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT02363400 2025-08-19
A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA
National Health Research Institutes, Taiwan
Phase 3 Terminated
NCT03034304 2025-07-24
A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
HRYZ Biotech Co.
Phase 1 Terminated
NCT02432378 2025-06-19
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT06140407 2025-06-05
Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT01720563 2025-06-04
A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy
PhytoHealth Corporation
Phase 2 Terminated
NCT03255252 2025-05-18
IMMUVIX
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Terminated
NCT01369641 2025-05-16
The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy
Thomas Jefferson University
Phase NA Terminated
NCT04870112 2025-04-17
SCope-D1
AstraZeneca
Phase 1 Terminated
NCT06094296 2025-04-16
A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 2 Terminated
NCT05179239 2025-04-15
A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Terminated
NCT03527264 2025-04-04
BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer
Brown University
Phase 2 Terminated
NCT04786964 2025-04-02
CONTERNO
Checkpoint Therapeutics, Inc.
Phase 3 Terminated
NCT04804696 2025-02-21
Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Terminated
NCT04213794 2025-02-20
TOASTIT
Mayo Clinic
Phase EARLY_PHASE1 Terminated
NCT04158141 2025-02-19
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
NRG Oncology
Phase 3 Terminated
NCT04364048 2024-12-20
Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 2 Terminated
NCT04951115 2024-11-26
A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer
Weill Medical College of Cornell University
Phase 2 Terminated
NCT02512692 2024-11-18
Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma
Medical University of South Carolina
Phase NA Terminated
NCT04287894 2024-11-06
Induction
The Netherlands Cancer Institute
Phase 1 Terminated
NCT04989218 2024-11-05
ICC
University of Alabama at Birmingham
Phase 1/2 Terminated
NCT01088906 2024-10-15
Phalcis
Spanish Lung Cancer Group
Phase 2 Terminated
NCT01285557 2024-09-19
DIGEST
Taiho Oncology, Inc.
Phase 3 Terminated
NCT04747470 2024-09-03
Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Terminated
NCT00791154 2024-08-23
SCLC
NantCell, Inc.
Phase 1/2 Terminated
NCT03387085 2024-08-09
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03387111 2024-08-05
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT02707666 2024-07-31
A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
University of Chicago
Phase 1 Terminated